Pharmaceutical Technology

SEPTEMBER 14, 2022

Currently, the company is making investments and obtaining crucial aspects of commercial-scale production and radioisotope supply. The company is also concluding more than 200 in vivo studies to gain insights and discover new drug candidates that could provide therapeutic radioisotopes for tumour-linked antigens.

In-Vivo 130

In-Vivo Clinical Trials Clinical Trials Engineer 130

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Croasdale-Wood will then participate in a keynote chat, interviewed by Miho.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Pharmaceutical Technology

SEPTEMBER 14, 2022

As an autologous cell therapy, manufacturing the infusion product is a highly specialised process involving tumour harvest and the extraction and large-scale ex vivo expansion of TILs. Tumour-infiltrating lymphocyte (TIL) therapy has been investigated as a treatment modality for melanoma for almost 20 years. months versus 3.1

Immune Response 246

Immune Response In-Vivo Production Manufacturing 246

Drug Discovery World

NOVEMBER 28, 2022

Neobe Therapeutics, an early-stage startup, has raised £520K ($628,000) in equity funding to engineer live biotherapeutics to remove barriers to immune infiltration in solid tumours. . While immunotherapies have revolutionised the treatment of cancer, the large majority of patients with solid tumours (up to 85%) still do not respond to them.

Engineer 52

Engineer In-Vivo Genetics Production 52

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

JUNE 27, 2023

We look forward to continuing our productive collaboration with our colleagues at IRBM in this compelling area of research.” Italian contract research organisation IRBM has signed a new agreement with Merck & Co Inc (MSD outside the USA and Canada) to continue their collaboration in the peptide therapeutics area.

In-Vivo 52

In-Vivo In-Vitro Engineer Protein 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 64

Antibody Engineer Protein Scientist 64

Pharmaceutical Technology

FEBRUARY 28, 2023

It was engineered with an Fc-silent IgG1 isotype to avoid activation of Fc-receptor-mediated non-specific immune. The bispecific antibody was found to conditionally activate the immune pathway in the tumour microenvironment in vitro and in vivo trials. Topic sponsors are not involved in the creation of editorial content.

In-Vivo 130

In-Vivo Antibody In-Vitro Licensing 130

pharmaphorum

APRIL 25, 2022

At the moment, it can take weeks to complete the CAR-T process, which includes harvesting of T cells from the patient an shipment to a manufacturing unit, engineering, activation, and expansion of the cells, quality control checks and shipment back to the hospital for re-infusion into the patient.

Engineer 97

Engineer In-Vivo FDA Approval Manufacturing 97

The Pharma Data

JANUARY 17, 2021

Based in Seattle, Washington, Sana focuses on in vivo and ex vivo cell engineering platforms to develop therapies for cancer, diabetes, cardiovascular disease, CNS disorders, and genetic diseases. Early-stage companies are often years, often a decade or longer, from a marketable product.

In-Vivo 52

In-Vivo Marketing Engineer Genetics 52

pharmaphorum

FEBRUARY 23, 2021

Advance Cutting-Edge Research and Development with Next-Generation Cell Therapies, to Deliver Best-in-Class Products to Patients in Need. Implement logic and develop ‘decision-making’ cells: create robust, controllable activation in vivo with University of Pennsylvania and Ludwig Institute for Cancer Research Lausanne.

In-Vivo 52

In-Vivo Engineer Development Production 52

Roots Analysis

SEPTEMBER 18, 2023

Owing to the ability to preserve a wide variety of elements for such a long period of time, including cells, tissues, blood and DNA, cryopreservation has emerged as a key focus area for stakeholders in the biopharmaceutical industry. Therefore, in order to store and preserve such enormous amounts of blood, single-use assemblies are a necessity.

Engineer 52

Engineer Containment In-Vivo Production 52

Drug Discovery World

NOVEMBER 30, 2023

DDW’s Megan Thomas attended PEGS Europe 2023 in Lisbon, Portugal, from Tuesday 14 November to Thursday 16 November 2023. The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows. GSK has developed high-throughput mammalian and E.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Drug Discovery World

NOVEMBER 15, 2022

The brainchild of multidisciplinary experts in computer science, physics, engineering, and biology, the field of synthetic biology has not only rapidly progressed in the last few decades but it’s also becoming more accessible and cost-effective. If there’s a mismatch between two strands, the DNA will melt away at a lower temperature.

DNA 98

DNA Drugs Antibody Engineer 98

Drug Discovery World

MARCH 12, 2024

Secondly, the programme has supported a focus on scientific excellence, which enabled us to release our study on the manufacturing of Velban from our engineered yeast cell factories as a proof-of- concept documenting Biomia’s biosynthesis platform. RA: Biomia is developing drug candidates for pain, addiction and mental health conditions.

Medicine 59

Medicine Production Drugs In-Vivo 59

Drug Discovery World

JANUARY 12, 2023

Altering one base pair can drastically change how the gene’s protein product functions, while mutations can lead to the development of a range of genetic disorders. . Altering one base pair can drastically change how the gene’s protein product functions, while mutations can lead to the development of a range of genetic disorders. .

Gene Editing 98

Gene Editing Gene Drugs In-Vivo 98

Roots Analysis

AUGUST 31, 2023

Several diseases are caused by sub-optimal gene expression or through uncoordinated or unsynchronized production of a gene product. Exogenous Gene Regulation Uncontrolled overexpression of exogenous genes often results in counter productivity when they are introduced into a host.

Gene 40

Gene Gene Therapy Gene Expression Regulation 40

Drug Discovery World

JUNE 14, 2023

MT: Where do you work, and can you tell us what you’re working on at the moment? We are a cell therapy company that uses a very specific receptor to engineer T cells and administer these engineered T cells back to solid tumour patients. We consider ourselves a next-generation engineered cell therapy company.

Research 52

Research Engineer In-Vivo Production 52

Drug Discovery World

AUGUST 14, 2023

While CGT is still an emerging market, its growth has accelerated over the last five years, resulting in a wave of products approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). And the robust CGT pipeline suggests there could be an influx of new approvals on the horizon. billion in 2020 to $15.5

Gene Therapy 52

Gene Therapy Marketing Gene DNA 52

Drug Discovery World

FEBRUARY 1, 2024

From this enriched selection, promising candidates are identified only after each antibody is characterised both in vitro and in vivo. Time can mean more than money when you’re studying a deadly pathogen. When all is said and done, this process may take months or years to complete.

Antibody 64

Antibody Gene Protein Manufacturing 64

Drug Discovery World

FEBRUARY 26, 2024

These therapies, which utilise human cells to replace diseased or damaged cells or use engineered cells to act as therapies for a specific disease, have become more common in recent years, with approvals and clinical trials increasing. It’s safe to say there is a lot of potential for cell therapies.

Manufacturing 52

Manufacturing In-Vivo Development Production 52

pharmaphorum

JANUARY 25, 2022

For example, there is no need for in vivo animal or in vitro pre-clinical or non-clinical studies. The area of digital therapeutics is growing rapidly, and in this piece Ben Hargreaves examines why this is the case, how broadly these therapies can be applied and why investment in the area is mounting. This equated to $21.3

Medicine 105

Medicine In-Vivo In-Vitro Development 105

Roots Analysis

DECEMBER 8, 2021

Biopreservation is the exclusive biological approach designated for the preservation of cells, tissues and organs ex-vivo for the purpose of storage, shipment and transportation. Biopreservation media is one of the most crucial entity in conferring effectiveness. F) to 8°C (46.4°F).

Packaging 52

Packaging Packaging In-Vivo Biobanking 52

XTalks

AUGUST 19, 2022

The road to Zynteglo’s approval was a bit rocky and included an FDA delay (the most recent in June) over production test concerns. The cells are prepared outside of the body ( ex vivo ) and then infused into the patient. Bluebird has a total of three gene therapies in its pipeline. Zynteglo’s hefty price tag of $2.8

Gene Therapy 95

Gene Therapy FDA Approval Gene Clinical Trials 95

The Pharma Data

JANUARY 4, 2021

USA) to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases. The companies will use ViGeneron’s proprietary vgAAV, novel engineered AAV capsids, to efficiently transduce retinal cells via intravitreal injections. . MUNICH, Germany, Jan. About ViGeneron.

Gene Therapy 52

Gene Therapy Gene Development In-Vivo 52

The Pharma Data

JANUARY 12, 2021

KSQ is also eligible to receive tiered royalties on net sales of each approved product. KSQ will have the option to participate in cost/profit sharing on one of the two products based on the T-cell targets previously identified and validated by KSQ, in the U.S. sales for that product. sales for that product.

Development 52

Development Research In-Vivo Genome 52

Drug Discovery World

JUNE 7, 2023

DDW’s Diana Spencer chats to Macomics’ co-founder and VP Immunology Dr Luca Cassetta about the company’s approach to tumour suppression and the challenges of launching a new business in early 2020. DS: Congratulations on the publication of your discoveries in Nature Reviews Cancer. Your studies focus on tumour associated macrophages (TAMs).

In-Vivo 52

In-Vivo Gene Editing Engineer Bioinformatics 52

Drug Discovery World

FEBRUARY 6, 2023

We isolate antibodies from single human B cells using single cell genomics and assess, engineer, and advance these antibodies with other technologies. DDW’s Megan Thomas caught up with Wyatt McDonnell, CEO and co-founder of Infinimmune. This has consequences for safety and efficacy.

Antibody 52

Antibody Immune Response Genome Genomics 52

Drug Discovery World

JANUARY 23, 2023

Increasing interest in CRISPR-Cas gene editing systems over recent years has delivered innovative developments in precision genome engineering technologies, holding enormous potential for applications across the healthcare sector.

Gene Editing 52

Gene Editing Gene Engineer DNA 52

FDA Law Blog

OCTOBER 10, 2023

Implant devices are used in a range of settings such as dental and orthopedic procedures. Having a clear understanding of FDA’s data expectations for 510(k) applications related to implants is crucial for successful marketing clearance. The intended duration of implantation is another crucial factor in performance testing.

In-Vivo 45

In-Vivo Manufacturing Engineer Genotoxicity 45

The Pharma Data

DECEMBER 9, 2020

With the launch of Overland, we are creating a robust research and development engine in parallel with the significant growth and opportunity presented by Asia’s evolving biotech industry. A solution could be at hand with Overland Pharmaceuticals. Below is a roundup of some of this week’s interesting news.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

Drug Discovery World

FEBRUARY 15, 2023

Sophisticated and continually evolving preclinical IO models (in vivo and in vitro) are particularly helpful in defining translational therapeutic strategies and understanding the efficacy of combination immunotherapies and refractory cancers, and in the identification of novel prognostic biomarkers. This continues to be the standard of care.

Research 52

Research In-Vitro In-Vivo Development 52

Drug Discovery World

SEPTEMBER 14, 2023

Excluding Covid-19 medicines, total revenue increased 16% and product sales increased 15%. Business updates Pfizer reported second quarter 2023 revenues totalling $12.7 billion, a decrease of $15.0 billion, or 54%, compared to the prior year quarter, reflecting an operational decline of $14.7 Vaccines were up 9.1%

Drugs 59

Drugs Vaccination Vaccine Medicine 59

XTalks

FEBRUARY 27, 2024

TIL vs CAR T-Cell Therapies While CAR T-cell therapies involve inserting a CAR engineered to target a specific cancer cell protein into a patient’s T cells, TIL-based T-cell therapies like Amtagvi involve separating TILs from a patient’s tumor (in autologous therapies) and expanding them ex vivo.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

Drug Discovery World

AUGUST 15, 2023

The objective of this proposal would be to identify the pro-arrhythmic side effects of potential new drugs for their earlier withdrawal from the lengthy drug discovery and development process, enabling the productivity of cardiovascular drug discovery to improve. Cardiovascular diseases are the leading cause of death globally.

Drugs 52

Drugs In-Vivo Development Research 52

Drug Discovery World

JULY 22, 2022

Psychedelic plants and fungi have been used medicinally by indigenous populations over thousands of years. Studies are now evaluating the use of psychedelics as integral parts of treatment approaches for psychiatric disorders ranging from depression and anxiety, to post-traumatic stress disorder.

Drugs 98

Drugs In-Vitro In-Vivo Clinical Trials 98

The Pharma Data

JANUARY 11, 2021

Our antibody clones in their original IgG format have shown potent neutralization activity in in vitro assays and, in the case of our lead clone, in an in vivo animal model. Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies.

Antibody 52

Antibody Licensing Licensing Development 52